SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is experiencing a surge in trading volume and social media interest as retail investors rally behind a 'Save Wendy's' campaign, targeting the stock's significant short interest for a potential squeeze. Community members are actively sharing takeover rumors, comparing the setup to previous meme stock rallies, and debating the company's long-term value alongside its dividend yield.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing significant volatility as community sentiment splits between retail investors seeking to buy the dip following technical breakdowns and traders closely monitoring institutional sell-side pressure. While recent strategic partnerships and government contract wins serve as fundamental catalysts, the conversation is currently dominated by aggressive discussions around potential support levels and the stock's sensitivity to broader tech sector rotations.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust is experiencing significant volatility as market participants debate whether recent price declines represent a fundamental shift or a temporary correction linked to broader economic uncertainty. Community discussions are heavily divided between long-term investors citing industrial shortages and physical accumulation as a floor, and traders expressing frustration over the asset's inability to sustain gains despite geopolitical headlines.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is experiencing high volatility as investors scrutinize its valuation and margin outlook following its first post-IPO earnings report. While the company announced a significant multi-year deal with OpenAI, community sentiment remains divided over concerns regarding share lockup expirations and the sustainability of its growth trajectory compared to established competitors.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is facing intense selling pressure as investors rotate out of gold, driven by concerns that persistent inflation and a strong dollar will force the Federal Reserve to maintain higher interest rates. The community is sharply divided, with bulls viewing the drop as a structural buying opportunity near key support levels, while bears are aggressively shorting the ETF, anticipating further downside as gold's safe-haven appeal wanes.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending following the announcement of a strategic agreement with Fit Energy to supply up to 380MW of clean, on-site power for AI data centers, with an immediate deposit for the first 30MW. While the community is debating the credibility of the partner and the structure of the deal, many bulls are focused on the validation of FCEL's utility-scale tech within the high-demand data center power sector.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is surging as investors react to high-profile executive orders prioritizing quantum technology, with community sentiment boosted by the CEO's direct participation in White House policy discussions. Traders are actively debating whether this momentum will trigger a sustained breakout, focusing heavily on potential institutional index inclusion and upcoming technical product updates.

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Absci Corp

Absci Corp is trending as investors react to positive interim phase 1 data for its hair loss antibody, ABS-201, alongside a new $100 million equity offering that includes participation from Eli Lilly. The community is heavily debating the stock's long-term potential in AI-driven drug discovery versus concerns over dilution and short-term price volatility.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is experiencing a significant surge following an agreement with Renew Home and Tesla to develop a large-scale virtual power plant, which the community sees as a major catalyst for grid infrastructure and AI-driven energy demand. Investors are actively discussing the stock's high short interest as a potential tailwind for further upward momentum and price discovery.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as investor anticipation builds around the company's obesity pipeline, particularly the Phase 3 VK2735 program and upcoming maintenance trial data. The community is actively debating the potential for an acquisition or partnership while analyzing strategic executive hires that suggest the firm is positioning itself for long-term commercialization and future drug combinations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Super Micro Computer, Summit Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

US stock futures lower, Nasdaq down 1%. Super Micro shares down 8.6% after announcing $7B offering to fund AI orders. Other stocks also down in pre-market trading.read more...

Why Is SMMT Stock Tumbling Today?

Equity

Summit announced a common stock offering, with underwriters having a 30-day option to purchase up to an additional $75 million of shares.

Summit Therapeutics Announces Proposed Public Offering of Common Stock

Summit Therapeutics Inc. (Nasdaq: SMMT) (Summit, we, or the Company) today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Summit. In addition, Summit intends to grant...

Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data

Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data...

Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 8, 2026. Members of the Summit management team will participate in a fireside chat presentation at 10:00 AM...

All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy

Summit Therapeutics (SMMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors Are Watching This High-Stakes Corner of Biotech

The race to improve therapies is heating up as Wall Street hunts for the next winners. NASDAQ:SPRC, NASDAQ:NTHI, NYSE:JNJ, NASDAQ:SMMT, NASDAQ:BNTX

Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments

Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments...

What's Going On With Summit Therapeutics Stock On Monday?

Summit Therapeutics' new ivonescimab trial results showed a survival benefit in lung cancer and encouraging data in colorectal cancer.read more...

Wall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a Bet

The consensus price target hints at a 67.1% upside potential for Summit Therapeutics (SMMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$14.27
Prev Close	$14.25
Open	$14.29
Dividend Yield	0.00%
50-Day Moving Average	$17.88
Beta	1.60
Avg. Volume	4.69M
PE Ratio	-8.89

52-Week High	$30.98
52-Week Low	$12.55
Market Capitalization	$11.06B
EPS (Annual)	-$1.44
Price to Book	20.26
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SMMTSummit Therapeutics Inc

Latest SMMT News